Ignite Creation Date:
2025-12-24 @ 6:48 PM
Ignite Modification Date:
2026-01-02 @ 12:50 PM
Study NCT ID:
NCT00398957
Status:
COMPLETED
Last Update Posted:
2010-04-27
First Post:
2006-11-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg
Sponsor:
Alza Corporation, DE, USA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
1998-09
Completion Date Type:
ACTUAL
First Submit Date:
2006-11-10
First Submit QC Date:
None
Study First Post Date:
2006-11-14
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2010-04-26
Last Update Post Date:
2010-04-27
Last Update Post Date Type:
ESTIMATED